<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330966</url>
  </required_header>
  <id_info>
    <org_study_id>AAPSMCS1002</org_study_id>
    <nct_id>NCT01330966</nct_id>
  </id_info>
  <brief_title>Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma</brief_title>
  <official_title>A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vector Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vector Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety of single agent
      pazopanib in subjects with chondrosarcoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control at week 16</measure>
    <time_frame>Assessed at week 16 of study treatment</time_frame>
    <description>Disease control at week 16 defined as complete response (CR) plus partial response (PR) plus stable disease (SD) where tumor response is defined by RECIST (Response Evaluation Criteria in Solid Tumors) guidelines version 1.1. Repeat radiologic imaging is performed after every 2 cycles of treatment (approximately every 8 weeks).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Continuously from the start of study treatment (Cycle 1 day 1) until 30 days after the end of treatment</time_frame>
    <description>Toxicity will be assessed continuously during study participation through the reporting of adverse events (AEs) using the CTCAE (Common Terminology Criteria for Adverse Events)version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Cycle 1 day 1 until the subject experiences disease progression</time_frame>
    <description>The time origin for PFS will be cycle 1 day 1. Repeat radiologic imaging will be conducted after every 2 cycles of treatment (approximately every 8 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Cycle 1 day 1 until 6 months after end of treatment, is lost to follow-up, or withdraws consent</time_frame>
    <description>The time origin for OS will be cycle 1 day 1. Subjects will be followed until 6 months after end of treatment, lost to follow-up, or withdrawal of consent.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Chondrosarcoma</condition>
  <condition>Metastatic Chondrosarcoma</condition>
  <arm_group>
    <arm_group_label>pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib</intervention_name>
    <description>Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.</description>
    <arm_group_label>pazopanib</arm_group_label>
    <other_name>Votrient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Age &gt; or = to 18 years.

          -  Histologically confirmed diagnosis of conventional chondrosarcoma of any grade.

          -  Surgically unresectable or metastatic disease.

          -  Any number of prior treatment regimens, including treatment naive subjects. Prior
             treatment with tyrosine kinase inhibitors is permitted.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

          -  Measurable or evaluable (non-measurable) disease per RECIST guidelines version 1.1.

          -  Adequate organ system function determined within 14 days prior to first dose of study
             treatment.

          -  Left ventricular ejection fraction &gt; 50% or the institutional LLN within 28 days prior
             to the first dose of study treatment.

          -  Females must either be of non-child bearing potential or have a negative serum
             pregnancy test within 7 days prior to the first dose of study treatment.

        Exclusion Criteria:

          -  Prior treatment with pazopanib.

          -  Mesenchymal, dedifferentiated, and extraskeletal myxoid chondrosarcoma subtypes.

          -  Prior malignancy (Note: subjects who have had another malignancy and have been
             disease-free for 3 years, or subjects with a history of completely resected
             non-melanomatous skin carcinoma or successfully treated in situ carcinoma are
             eligible).

          -  History or clinical evidence of central nervous system (CNS) metastases or
             leptomeningeal carcinomatosis, unless previously treated, asymptomatic, and off
             steroids and anti-seizure medication for 6 months prior to first dose of study drug.

          -  Clinically significant gastrointestinal (GI) abnormalities that may increase the risk
             for GI bleeding.

          -  Clinically significant GI abnormalities that may affect absorption of investigational
             product.

          -  Presence of uncontrolled infection.

          -  Corrected QT interval &gt; 480 msecs using Bazett's formula.

          -  History of certain cardiovascular conditions within the past 6 months.

          -  Poorly controlled hypertension [defined as systolic blood pressure of &gt; or = 140 mmHg
             or diastolic blood pressure of &gt; or = 90 mmHg].

          -  History of cerebrovascular accident including transient ischemic attack, pulmonary
             embolism, or untreated deep venous thrombosis within the past 6 months.

          -  Prior major surgery or trauma within 28 days prior to the first dose of study drug
             and/or presence of any non-healing wound, fracture, or ulcer.

          -  Evidence of active bleeding or bleeding diathesis.

          -  Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that
             increase the risk of pulmonary hemorrhage.

          -  Hemoptysis in excess of 2.5 mL within 8 weeks of first dose of study drug.

          -  Any serious and/or unstable pre-existing medical, psychiatric, or other condition that
             could interfere with subject's safety, provision of informed consent, or compliance to
             study procedures.

          -  Unable or unwilling to discontinue use of prohibited medications for at least 14 days
             or five half-lives of a drug (whichever is longer) prior to the first dose of study
             drug and for the duration of study treatment.

          -  Radiation therapy, surgery (except major surgery), tumor embolization, chemotherapy,
             immunotherapy, biologic therapy, investigational therapy, or hormonal therapy within
             14 days or five half-lives of a drug (whichever is longer) prior to the first dose of
             study drug.

          -  Any ongoing toxicity from prior anti-cancer therapy that is &gt; Grade 1 and/or that is
             progressing in severity, except alopecia.

          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to pazopanib or excipients that contraindicates participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur Staddon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pennsylvania Oncology Hematology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Warren Chow, MD</last_name>
    <role>Study Chair</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Cancer Center</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Oncology Hematology Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre</name>
      <address>
        <city>Edgbaston</city>
        <state>Birmingham</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2011</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>surgically unresectable chondrosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chondrosarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

